1. Sodium glucose co-transporter-2 inhibitor, empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1C levels in type 2 diabetic patients with established coronary heart disease: the SUPER GATE study;Bilgin;Ir J Med Sci,2022
2. Treatment of type 2 diabetes patients with heart conditions;Aktas;Expert Review of Endocrinology & Metabolism,2023
3. European Medicines Agency . Review of diabetes medicines called Sglt2 inhibitors started: risk of diabetic ketoacidosis to be examined. 2015. Available: https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-article-20-procedure-review-started_en.pdf [Accessed 31 Jul 2023].
4. Health Canada. Forxiga, Invokana . Health Canada begins safety review of diabetes drugs known as SGLT2 inhibitors and risk of ketoacidosis. Ottawa, ON: Health Canada, 2015. Available: https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-sglt2-inhibitors-canagliflozin-dapagliflozin-empagliflozin.html
5. US Food Drug Administration . FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Drug safety communications. 2015. Available: https://wwwfdagov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious#:~:text=%5B12%2D4%2D2015%5D,of%20serious%20urinary%20tract%20infections